Understanding Disease Pathology: Growing Rate of Toxicology Research is Driving the Demand for Peripheral Blood Mononuclear Cells
August 10, 2023 04:13 ET
|
Research and Markets
Dublin, Aug. 10, 2023 (GLOBE NEWSWIRE) -- The "Peripheral Blood Mononuclear Cells Market - Global Industry Size, Share, Trends, Opportunity and Forecasts to 2027" report has been added to ...
Salarius Pharmaceuticals Announces Plans to Explore Strategic Alternatives and Implement Measures to Extend its Resources
August 08, 2023 16:05 ET
|
Salarius Pharmaceuticals, Inc.
HOUSTON, Aug. 08, 2023 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage biopharmaceutical company using protein inhibition and protein degradation to develop...
Monocyte Activation Test Market to Expand at a 19.6% CAGR from 2023 to 2031, reaching US$ 305.3 million: TMR Report
July 31, 2023 10:30 ET
|
Transparency Market Research
Wilmington, Delaware, United States, July 31, 2023 (GLOBE NEWSWIRE) -- The global monocyte activation test market is anticipated to grow at a 19.6% CAGR from 2023 to 2031. A market valuation of US$...
Vaccitech to Present Positive Final Data at EASL Congress for Phase 1b/2 HBV002 Study in Adults with Chronic Hepatitis B
June 21, 2023 09:03 ET
|
Vaccitech plc
Meaningful, durable reductions of HBsAg were seen, both in participants who received VTP-300 alone and in combination with a low-dose PD-1 inhibitorTwo patients developed a non-detectable HBsAg level,...
Global Peripheral Blood Mononuclear Cells Market Assessment, By Product, By Application, By Techniques, By Source, By Region, Opportunities, and Forecast, 2016-2030F
June 15, 2023 10:19 ET
|
ReportLinker
New York, June 15, 2023 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Global Peripheral Blood Mononuclear Cells Market Assessment, By Product, By Application, By...
Kymera Therapeutics’ STAT3 Degrader KT-333 and IRAKIMiD Degrader KT-413 Demonstrate Desired Target Knockdown and Safety with Continued Dose Escalation in Ongoing Phase I Clinical Trials
June 14, 2023 02:30 ET
|
Kymera Therapeutics, Inc.
Data shared today on PK/PD and safety from additional KT-333 and KT-413 patient dose escalation cohorts show target knockdown at or near levels associated with clinical efficacy in preclinical tumor...
Salarius Pharmaceuticals Presents SP-3164 Targeted Protein Degrader Preclinical Data at the European Hematology Association 2023 Hybrid Congress
June 12, 2023 08:00 ET
|
Salarius Pharmaceuticals, Inc.
HOUSTON, June 12, 2023 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (NASDAQ: SLRX), a clinical-stage biopharmaceutical company using protein inhibition and protein degradation to develop...
Kymera Therapeutics Announces Updated Clinical Data from the Phase 1 Trials of STAT3 Degrader KT-333 and IRAKIMiD Degrader KT-413
June 09, 2023 18:00 ET
|
Kymera Therapeutics, Inc.
Data shared today in abstracts from the International Conference on Malignant Lymphoma (ICML) Both programs continue to demonstrate substantial target knockdown in ongoing clinical trials, with no...
Treos Bio Announces Presentation of Final Results from Phase 1b Study of PolyPEPI1018 Immunotherapy for Late-Stage Metastatic Colorectal Cancer at 2023 American Society of Clinical Oncology (ASCO) Annual Meeting
June 05, 2023 09:00 ET
|
Treos Bio Limited
LONDON, June 05, 2023 (GLOBE NEWSWIRE) -- Treos Bio Limited (“Treos”), a clinical stage biotechnology company using data science and proprietary biomarkers to develop precision peptide...
Global Humanized Mouse and Rat Model Market Report 2023: Rising Demand for Humanized PDX Models Presents Opportunities
May 22, 2023 10:33 ET
|
Research and Markets
Dublin, May 22, 2023 (GLOBE NEWSWIRE) -- The "Global Humanized Mouse and Rat Model Market by Type (Genetic, Cell-based (CD34, PBMC, BLT)), Application (Neuroscience, Oncology, Toxicology, Immunology...